2026 Primary peritoneal cancer strategy: epidemiology, FOLR1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 HER2-low breast cancer strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zaltenibart, an antibody targeting MASP-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vipalanebart, an antibody targeting ADCYAP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Verekitug, an antibody targeting CRLF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Venanprubart, an antibody targeting BTLA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vebanvibart, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Umikibart, an antibody targeting HGF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ucenprubart, an antibody targeting MOX2R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Traxivitug, an antibody targeting BK Polyomavirus Major Capsid Protein VP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pacibekitug, an antibody targeting IL6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozureprubart, an antibody targeting IgE.